-
Subject Areas on Research
-
(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis.
-
(18)F-Flourodeoxy-Glucose PET/Computed Tomography in Brain Tumors: Value to Patient Management and Survival Outcomes.
-
(18)F-fluorodeoxyglucose positron emission tomography and MR imaging findings in Rasmussen encephalitis.
-
(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.
-
18-Fluorodeoxyglucose positron emission tomography in children and adolescents with traumatic brain injury.
-
18F FDG PET/CT and Head and Neck Cancer: Patient Management and Outcomes.
-
18F-FDG PET/CT Metabolic Tumor Volume and Intratumoral Heterogeneity in Pancreatic Adenocarcinomas: Impact of Dual-Time Point and Segmentation Methods.
-
18F-FDG PET/CT Prediction of Treatment Outcomes in Human Papillomavirus-Positive, Locally Advanced Oropharyngeal Cancer Patients Receiving Deintensified Therapy: Results from NRG-HN002.
-
18F-FDG PET/CT Staging of Head and Neck Cancer: Interobserver Agreement and Accuracy-Results from Multicenter ACRIN 6685 Clinical Trial.
-
18F-FDG PET/CT and Melanoma: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management.
-
18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients.
-
18F-FDG PET/CT: Therapy Response Assessment Interpretation (Hopkins Criteria) and Survival Outcomes in Lung Cancer Patients.
-
18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging.
-
18F-FDG-PET/CT Imaging for Gastrointestinal Malignancies.
-
18F-FDG-PET/CT therapy assessment of locally advanced pancreatic adenocarcinoma: impact on management and utilization of quantitative parameters for patient survival prediction.
-
18F-fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma.
-
1999 plenary session: Friday imaging symposium : evaluation of focal pulmonary abnormalities with FDG PET.
-
2-Deoxy-2-[18F] Fluoro-d-Glucose PET/Computed Tomography: Therapy Response Assessment in Head and Neck Cancer.
-
A General Cutoff Level Combined With Personalized Dynamic Change of Serum Carcinoembryonic Antigen Can Suggest Timely Use of FDG PET for Early Detection of Recurrent Colorectal Cancer.
-
A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients.
-
A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma.
-
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.
-
A novel metric for quantification of homogeneous and heterogeneous tumors in PET for enhanced clinical outcome prediction.
-
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).
-
A systematic review of the factors affecting accuracy of SUV measurements.
-
ACR Appropriateness Criteria® Staging and Follow-Up of Esophageal Cancer.
-
ACR Appropriateness Criteria® Suspected Pulmonary Hypertension.
-
AJR teaching file: incidental breast cancer detected with 18F-FDG PET/CT.
-
Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy.
-
Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease.
-
Accuracy of surface fit registration for PET and MR brain images using full and incomplete brain surfaces.
-
Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: a retrospective analysis with follow-up for 12 years.
-
Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm.
-
Advances in Lung Cancer Imaging.
-
Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers.
-
Alzheimer disease: operating characteristics of PET--a meta-analysis.
-
Ameloblastic carcinoma of the mandible with metastasis to the skull and lung: advanced imaging appearance including computed tomography, magnetic resonance imaging and positron emission tomography computed tomography.
-
An Adipose Tissue Atlas: An Image-Guided Identification of Human-like BAT and Beige Depots in Rodents.
-
Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value.
-
Apolipoprotein E Mimetic Peptide Increases Cerebral Glucose Uptake by Reducing Blood-Brain Barrier Disruption after Controlled Cortical Impact in Mice: An 18F-Fluorodeoxyglucose PET/CT Study.
-
Appropriate Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease.
-
Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults.
-
Association Between Aortic Vascular Inflammation and Coronary Artery Plaque Characteristics in Psoriasis.
-
Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis: A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography.
-
Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers.
-
Association of Interim FDG-PET Imaging During Chemoradiation for Squamous Anal Canal Carcinoma With Recurrence.
-
Attenuation correction in hybrid positron emission tomography.
-
Better late than early: FDG-PET imaging in metastatic renal cell carcinoma.
-
Bidirectional Changes in Myocardial 18F-Fluorodeoxyglucose Uptake After Human Ventricular Unloading.
-
Brain FDG PET and the diagnosis of dementia.
-
Cardiovascular Imaging With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients With Fibroinflammatory Disorders.
-
Case 260: Endobronchial Posttransplantation Lymphoproliferative Disease.
-
Cerebral imaging of decompression injury patients with 18-F-2-fluoro-2-deoxyglucose positron emission tomography.
-
Changes on Midchemoradiation Therapy Fluorodeoxyglucose Positron Emission Tomography for Cervical Cancer Are Associated with Prognosis.
-
Characteristic patterns of inter- and intra-hemispheric metabolic connectivity in patients with stable and progressive mild cognitive impairment and Alzheimer's disease.
-
Chronic Stress-Related Neural Activity Associates With Subclinical Cardiovascular Disease in Psoriasis: A Prospective Cohort Study.
-
Clinical Indications and Impact on Management: Fourth and Subsequent Posttherapy Follow-up 18F-FDG PET/CT Scans in Oncology Patients.
-
Clinical Practice in PET/CT for the Management of Head and Neck Squamous Cell Cancer.
-
Clinical and Technical Considerations for Brain PET Imaging for Dementia.
-
Clinical oncologic positron emission tomography: an introduction.
-
Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer.
-
Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland.
-
Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence.
-
Clinical utility of positron emission tomography in the diagnosis and management of periampullary neoplasms.
-
Clinical, 18F-dopa PET, and genetic analysis of an ethnic Chinese kindred with early-onset parkinsonism and parkin gene mutations.
-
Colonic schwannoma visualized on FDG PET/CT.
-
Combined deletion of Glut1 and Glut3 impairs lung adenocarcinoma growth.
-
Combining multiple FDG-PET radiotherapy target segmentation methods to reduce the effect of variable performance of individual segmentation methods.
-
Commentary on "Positron Emission Tomography in the Lung" 25 years after publication in the inaugural issue of the Journal of Thoracic Imaging.
-
Comparative effectiveness: 18F-FDG-PET/CT versus CT for post-treatment follow-up of patients with lung cancer.
-
Comparison of Exogenous Ketone Administration Versus Dietary Carbohydrate Restriction on Myocardial Glucose Suppression: A Crossover Clinical Trial.
-
Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.
-
Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer.
-
Comprehensive nutrient consumption estimation and metabolic profiling during ketogenic diet and relationship with myocardial glucose uptake on FDG-PET.
-
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.
-
Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma.
-
Correction for partial volume effects in regional blood flow measurements adjacent to hematomas in humans with intracerebral hemorrhage: implementation and validation.
-
Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer.
-
Correlation of [18F]-2-fluoro-deoxy-D-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer.
-
Correlation of hippocampal neuronal density and FDG-PET in mesial temporal lobe epilepsy.
-
Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules.
-
Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
-
Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience.
-
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin.
-
Diagnosing pulmonic valve infective endocarditis with positron emission tomography-CT.
-
Diagnosis of pancreatic carcinoma: role of FDG PET.
-
Diagnostic Accuracy of Follow-Up FDG PET or PET/CT in Patients With Head and Neck Cancer After Definitive Treatment: A Systematic Review and Meta-Analysis.
-
Dose-dependent effects of radiation therapy on cerebral blood flow, metabolism, and neurocognitive dysfunction.
-
Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance.
-
Dual-Energy CT Vital Iodine Tumor Burden for Response Assessment in Patients With Metastatic GIST Undergoing TKI Therapy: Comparison With Standard CT and FDG PET/CT Criteria.
-
Dynamic prognostication using conditional survival analysis for patients with operable lung adenocarcinoma.
-
Early 18F-FDG-PET Response During Radiation Therapy for HPV-Related Oropharyngeal Cancer May Predict Disease Recurrence.
-
Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma.
-
Early recognition of Alzheimer's disease: what is consensual? What is controversial? What is practical?
-
Effect of Immunosuppressive Therapy and Biopsy Status in Monitoring Therapy Response in Suspected Cardiac Sarcoidosis.
-
Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction.
-
Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium.
-
Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography.
-
Evaluation of patients with round atelectasis using 2-[18F]-fluoro-2-deoxy-D-glucose PET.
-
Evaluation of primary pulmonary carcinoid tumors using FDG PET.
-
Evolving role of FDG PET/CT in multiple myeloma imaging and management.
-
F-18 FDG PET/CT imaging of a hidradenocarcinoma of head and neck.
-
F-18 FDG PET/CT imaging of a parapharyngeal hemangioma.
-
F-18 FDG PET/CT imaging of endogenous Cushing syndrome.
-
F-18 FDG PET/CT imaging of intraventricular germinoma.
-
F-18 FDG PET/CT imaging of submandibular gland oncocytoma.
-
F-18-FDG-PET/CT imaging of small cell carcinoma of the colon.
-
FDG Avidity and Tumor Burden: Survival Outcomes for Patients With Recurrent Breast Cancer.
-
FDG PET imaging in patients with pathologically verified dementia.
-
FDG PET metabolic tumor volume segmentation and pathologic volume of primary human solid tumors.
-
FDG PET of pleural effusions in patients with non-small cell lung cancer.
-
FDG PET/CT for Management and Assessing Outcomes of Squamous Cell Cancer of the Oral Cavity.
-
FDG PET/CT for Primary Staging of Lung Cancer and Mesothelioma.
-
FDG PET/CT imaging of oropharyngeal squamous cell carcinoma: characteristics of human papillomavirus-positive and -negative tumors.
-
FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes.
-
FDG PET/CT in Patients With Head and Neck Squamous Cell Carcinoma After Primary Surgical Resection With or Without Chemoradiation Therapy.
-
FDG PET/CT in patients with HIV.
-
FDG PET/CT in the management of colorectal and anal cancers.
-
FDG PET/CT in the management of nasopharyngeal carcinoma.
-
FDG PET/CT in the management of primary pleural tumors and pleural metastases.
-
FDG PET/CT interobserver agreement in head and neck cancer: FDG and CT measurements of the primary tumor site.
-
FDG PET/CT of carcinoma showing thymus-like differentiation.
-
FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer.
-
FDG imaging of lung nodules: a phantom study comparing SPECT, camera-based PET, and dedicated PET.
-
FDG volumetric parameters and survival outcomes after definitive chemoradiotherapy in patients with recurrent head and neck squamous cell carcinoma.
-
FDG-PET assessment of the effect of head and neck radiotherapy on parotid gland glucose metabolism.
-
FDG-PET finding in early-phase Takayasu arteritis.
-
FDG-PET for management of cervical and ovarian cancer.
-
FDG-PET imaging in patients with paraneoplastic syndromes and suspected small cell lung cancer.
-
FDG-PET imaging in patients with pulmonary carcinoid tumor.
-
FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS.
-
FDG-PET in pediatric posterior fossa brain tumors.
-
FDG-PET in the selection of brain lesions for biopsy.
-
FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume.
-
FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
-
FDG-PET/CT and Pathology in Newly Diagnosed Head and Neck Cancer: ACRIN 6685 Trial, FDG-PET/CT cN0.
-
FDG-PET/CT characterization of adrenal nodules: diagnostic accuracy and interreader agreement using quantitative and qualitative methods.
-
False-negative findings for primary lung tumors on FDG positron emission tomography: staging and prognostic implications.
-
Feasibility of optimizing the dose distribution in lung tumors using fluorine-18-fluorodeoxyglucose positron emission tomography and single photon emission computed tomography guided dose prescriptions.
-
Fluorodeoxyglucose positron emission tomography/computerized tomography in differentiated thyroid cancer management: Importance of clinical justification and value in predicting survival.
-
Fluorodeoxyglucose-positron-emission tomography imaging of head and neck squamous cell cancer.
-
Focal F-18 fluoro-deoxy-glucose accumulation in the lung parenchyma in the absence of CT abnormality in PET/CT.
-
Focal cerebral metabolic abnormality in a patient with continuous spike waves during slow-wave sleep.
-
Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning.
-
Follow-up FDG PET/CT in Patients With Non-Hodgkin Lymphoma: Value to Clinical Assessment and Patient Management.
-
Follow-up or Surveillance (18)F-FDG PET/CT and Survival Outcome in Lung Cancer Patients.
-
Fortuitous detection of papillary carcinoma of the thyroid with F-18 FDG positron emission tomography in a patient with non-Hodgkin lymphoma.
-
Ga-68 DOTATATE PET/CT and F-18 FDG PET/CT in the evaluation of low and intermediate versus high-grade neuroendocrine tumors.
-
Gangliogliomas: characterization by registered positron emission tomography-MR images.
-
Gated 99mTc-tetrofosmin and 18F-FDG studies: a comparison of single-acquisition and separate-acquisition protocols.
-
Giant cell arteritis mimicking infiltrative leptomeningeal disease of the optic nerves.
-
Head and Neck Cancer and PET/Computed Tomography.
-
Head and neck PET/CT: therapy response interpretation criteria (Hopkins Criteria)-interreader reliability, accuracy, and survival outcomes.
-
Head and neck cancer: dedicated FDG PET/CT protocol for detection--phantom and initial clinical studies.
-
Head and neck squamous cell cancer (stages III and IV) induction chemotherapy assessment: value of FDG volumetric imaging parameters.
-
Hibernoma: 18F FDG PET/CT imaging.
-
Home surveillance program prevents interstage mortality after the Norwood procedure.
-
Human herpesvirus 6 limbic encephalitis after stem cell transplantation.
-
I-131, I-123, and F-18 FDG-PET imaging in a patient with diffuse sclerosing variant of papillary thyroid cancer.
-
IV Contrast Material for PET/CT: Point-Putting the CT Into PET/CT.
-
Identification of distant metastases with positron-emission tomography-computed tomography in patients with previously untreated head and neck cancer.
-
Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography.
-
Imaging biomarker roadmap for cancer studies.
-
Imaging of mediastinal lymph nodes: CT, MR, and FDG PET.
-
Imaging-guided preoperative hookwire localization of nonpalpable extramammary lesions.
-
Impact of Neck PET/CT Positivity on Survival Outcomes-Visual and Quantitative Assessment: Results From ACRIN 6685.
-
Impact of point spread function reconstruction on quantitative 18F-FDG-PET/CT imaging parameters and inter-reader reproducibility in solid tumors.
-
Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry.
-
In vivo noninvasive detection of Brown Adipose Tissue through intermolecular zero-quantum MRI.
-
In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
-
Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma.
-
Increasing uptake time in FDG-PET: standardized uptake values in normal tissues at 1 versus 3 h.
-
Influence of filter choice on 18F-FDG PET segmentation accuracy determined using generalized estimating equations.
-
Interesting image. F-18 fluorodeoxyglocose positron emission tomography/computed tomography in the diagnosis of chronic myopathic sarcoidosis.
-
Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?
-
Interpretation variability of 18FDG-positron emission tomography studies in dementia.
-
Interreader agreement and variability of FDG PET volumetric parameters in human solid tumors.
-
Intra-reader reliability of FDG PET volumetric tumor parameters: effects of primary tumor size and segmentation methods.
-
Intraarterial Microdosing: A Novel Drug Development Approach, Proof-of-Concept PET Study in Rats.
-
Intratherapy or Posttherapy FDG PET or FDG PET/CT for Patients With Head and Neck Cancer: A Systematic Review and Meta-analysis of Prognostic Studies.
-
Intratreatment Response Assessment With 18F-FDG PET: Correlation of Semiquantitative PET Features With Pathologic Response of Esophageal Cancer to Neoadjuvant Chemoradiotherapy.
-
Intratumoral Metabolic Heterogeneity and Other Quantitative 18F-FDG PET/CT Parameters for Prognosis Prediction in Esophageal Cancer.
-
Intrinsic radiomic expression patterns after 20 Gy demonstrate early metabolic response of oropharyngeal cancers.
-
Is chronically dysfunctional yet viable myocardium distal to a severe coronary stenosis hypoperfused?
-
Is follow-up CT imaging of the chest and abdomen necessary after preoperative neoadjuvant therapy in rectal cancer patients without evidence of metastatic disease at diagnosis?
-
Ischemic hibernating myocardium demonstrated by positron emission tomography in anomalous origin of the left coronary artery from the pulmonary artery.
-
Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis.
-
JOURNAL CLUB: Value of Quantitative FDG PET/CT Volumetric Biomarkers in Recurrent Colorectal Cancer Patient Survival.
-
Joint SNMMI-ASNC Expert Consensus Document on the Role of 18F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring.
-
Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring.
-
Kaposi sarcoma after bilateral lung transplantation.
-
Late Gadolinium Enhancement Cardiac Magnetic Resonance Tissue Characterization for Cancer-Associated Cardiac Masses: Metabolic and Prognostic Manifestations in Relation to Whole-Body Positron Emission Tomography.
-
Limbic encephalitis: comparison of FDG PET and MR imaging findings.
-
Linking dementia research to policy: an example using fluorodeoxyglucose positron emission tomography for the diagnosis of Alzheimer's dementia and mild cognitive impairment.
-
Liver SULmean at FDG PET/CT: interreader agreement and impact of placement of volume of interest.
-
Liver standardized uptake value corrected for lean body mass at FDG PET/CT: effect of FDG uptake time.
-
Local recurrence of rectal cancer: evaluation with F-18 fluorodeoxyglucose PET imaging.
-
Locally increased uptake of fluorine-18-fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors.
-
Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.
-
Lung Cancer Recurrence: 18F-FDG PET/CT in Clinical Practice.
-
Lung Cancers Associated With Cystic Airspaces: Natural History, Pathologic Correlation, and Mutational Analysis.
-
Lung cancer and positron emission tomography with fluorodeoxyglucose.
-
Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography.
-
Melanoma patients evaluated by four different positron emission tomography reconstruction techniques.
-
Meta-analysis: the detection of pancreatic malignancy with positron emission tomography.
-
Metastatic melanoma to the heart.
-
Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics.
-
Molecular Imaging and Precision Medicine in Head and Neck Cancer.
-
Molecular Imaging and Precision Medicine: PET/Computed Tomography and Therapy Response Assessment in Oncology.
-
Molecular imaging in Alzheimer's disease.
-
Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET.
-
Multicenter Trial of [18F]fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging of Head and Neck Cancer and Negative Predictive Value and Surgical Impact in the N0 Neck: Results From ACRIN 6685.
-
Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.
-
Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer's Disease using structural MR and FDG-PET images.
-
Neuronal migration disorders: positron emission tomography correlations.
-
Non-invasive sensitive brain tumor detection using dual-modality bioimaging nanoprobe.
-
Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
-
Normal brain F-18 FDG-PET and MRI anatomy.
-
Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis.
-
Oncogene pathway activation in mammary tumors dictates FDG-PET uptake.
-
Oncologic 18F-FDG PET/CT: referring physicians' point of view.
-
PET Imaging for Head and Neck Cancers.
-
PET Imaging of Oral Cavity and Oropharyngeal Cancers.
-
PET and brain tumor image fusion.
-
PET appearance of tuberculous empyema necessitans.
-
PET imaging in patients with bronchioloalveolar cell carcinoma.
-
PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions.
-
PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer.
-
PET-detected asymptomatic recurrence is associated with improved survival in recurrent cervical cancer.
-
PET/CT mediastinal and liver FDG uptake: effects of biological and procedural factors.
-
PET/CT of Dementia.
-
PET/CT of cancer patients: part 1, pancreatic neoplasms.
-
PET/CT of cancer patients: part 2, deformable registration imaging before and after chemotherapy for radiation treatment planning in head and neck cancer.
-
PET/CT today and tomorrow in veterinary cancer diagnosis and monitoring: fundamentals, early results and future perspectives.
-
PET/Computed Tomography Scanning and Precision Medicine: Esophageal Cancer.
-
PET/Computed Tomography and Precision Medicine: Gastric Cancer.
-
PET/Computed Tomography and Precision Medicine: Musculoskeletal Sarcoma.
-
PET/Computed Tomography: Laryngeal and Hypopharyngeal Cancers.
-
PET/Computed Tomography: Post-therapy Follow-up in Head and Neck Cancer.
-
Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters.
-
Perceived misinterpretation rates in oncologic 18F-FDG PET/CT studies: a survey of referring physicians.
-
Perineural spread of melanoma demonstrated by F-18 FDG PET With MRI and pathologic correlation.
-
Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose.
-
Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC).
-
Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy.
-
Platelet mitochondrial complex I and I+III activities do not correlate with cerebral mitochondrial oxidative metabolism.
-
Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease.
-
Positron emission tomography detection of metastatic penile squamous cell carcinoma.
-
Positron emission tomography imaging in the thorax.
-
Positron emission tomography imaging of brain tumors.
-
Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.
-
Positron emission tomography in hepatobiliary and pancreatic malignancies: a review.
-
Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings.
-
Positron emission tomography scanning in malignant melanoma.
-
Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer.
-
Positron emission tomography with fluoro-2-deoxy-D-glucose (FDG-PET) in the staging of post transplant lymphoproliferative disorder in lung transplant recipients.
-
Positron emission tomography: brain tumors and lung cancer.
-
Post-treatment 18F-FDG-PET/CT versus contrast-enhanced CT in patients with oropharyngeal squamous cell carcinoma: comparative effectiveness study.
-
Precision Medicine and PET-Computed Tomography in Pediatric Malignancies.
-
Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers.
-
Prediction of lung malignancy progression and survival with machine learning based on pre-treatment FDG-PET/CT.
-
Pretreatment 18F-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Values and Tumor Size in Medically Inoperable Nonsmall Cell Lung Cancer Is Prognostic of Overall 2-Year Survival After Stereotactic Body Radiation Therapy.
-
Primary muscle lymphoma: clinical and imaging findings.
-
Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project.
-
Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data.
-
Prognosis of conversion of mild cognitive impairment to Alzheimer's dementia by voxel-wise Cox regression based on FDG PET data.
-
Prognostic Value of FDG PET/CT-Derived Parameters in Pancreatic Adenocarcinoma at Initial PET/CT Staging.
-
Prognostic modeling for patients with colorectal liver metastases incorporating FDG PET radiomic features.
-
Prognostic significance of parameters derived from co-registered 18F-fluorodeoxyglucose PET and contrast-enhanced MRI in patients with high-grade glioma.
-
Prognostic value of FDG PET metabolic tumor volume in human papillomavirus-positive stage III and IV oropharyngeal squamous cell carcinoma.
-
Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
-
Prognostic value of midtreatment FDG-PET in oropharyngeal cancer.
-
Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer.
-
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.
-
Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases.
-
Prospective investigation of positron emission tomography in lung nodules.
-
Pulmonary abnormalities and PET data analysis: a retrospective study.
-
Quantitative PET/CT in clinical practice: assessing the agreement of PET tumor indices using different clinical reading platforms.
-
Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease?
-
Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
-
Reasons Associated with Total Thyroidectomy as Initial Surgical Management of an Indeterminate Thyroid Nodule.
-
Recent developments in predicting thyroid malignancy.
-
Recommendations on the use of 18F-FDG PET in oncology.
-
Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer's Dementia.
-
Regional brain activity correlates of nicotine dependence.
-
Regional cerebral blood flow and metabolic rate in persistent Lyme encephalopathy.
-
Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials.
-
Reply to "Prognostic Value of Fluorodeoxyglucose-Positron Emission Tomography".
-
Reply: Repeatability of Tumor SUV Quantification: The Role of Variable Blood SUV.
-
Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer.
-
Role of 18 F-FDG PET/CT differentiating olfactory neuroblastoma from sinonasal undifferentiated carcinoma.
-
Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung Cancer.
-
Role of Non-FDG-PET/CT in Head and Neck Cancer.
-
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer.
-
Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis.
-
Schwannoma in neurofibromatosis type 1: a pitfall for detecting malignancy by metabolic imaging.
-
Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy.
-
Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities.
-
Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer.
-
Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.
-
Spatiotemporal distribution modeling of PET tracer uptake in solid tumors.
-
Squamous cell carcinoma of the palatine tonsils: FDG standardized uptake value ratio as a biomarker to differentiate tonsillar carcinoma from physiologic uptake.
-
Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo.
-
Staging non-small cell lung cancer with whole-body PET.
-
Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.
-
T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET.
-
Talc pleurodesis simulating pleural metastases on 18F-fluorodeoxyglucose positron emission tomography.
-
Task Group 174 Report: Utilization of [18 F]Fluorodeoxyglucose Positron Emission Tomography ([18 F]FDG-PET) in Radiation Therapy.
-
Temporal lobe hypometabolism on PET: predictor of seizure control after temporal lobectomy.
-
Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors.
-
The QIBA Profile for FDG PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy.
-
The Value of FDG PET/CT in Treatment Response Assessment, Follow-Up, and Surveillance of Lung Cancer.
-
The added value of 18F-FDG PET/CT for evaluation of patients with esthesioneuroblastoma.
-
The effect of metabolic milieu on cardiac PET imaging using fluorine-18-deoxyglucose and nitrogen-13-ammonia in normal volunteers.
-
The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans.
-
The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma.
-
The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events.
-
The role of F-18 FDG positron emission tomography in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer.
-
The role of PET scanning in the detection of recurrent cervical cancer.
-
The role of PET/CT in the management of cervical cancer.
-
The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas.
-
The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study.
-
The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma.
-
The value of follow-up FDG-PET/CT in the management and prognosis of patients with HPV-positive oropharyngeal squamous cell carcinoma.
-
The value of fourth and subsequent post-treatment 18F-FDG PET/CT scans in the management of patients with non-Hodgkin's lymphoma.
-
Therapy Response Assessment and Patient Outcomes in Head and Neck Squamous Cell Carcinoma: FDG PET Hopkins Criteria Versus Residual Neck Node Size and Morphologic Features.
-
Thoracic FDG PET: state of the art.
-
Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma.
-
Transient focal increase in perihematomal glucose metabolism after acute human intracerebral hemorrhage.
-
Transmission scanning system for a gamma camera coincidence scanner.
-
Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: a comparison with 15O-labeled water-measured blood flow.
-
Two-time-point FDG PET/CT: liver SULmean repeatability.
-
Update 2018: 18F-FDG PET/CT and PET/MRI in Head and Neck Cancer.
-
Use of 18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma.
-
Use of 18F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography for Patient Management and Outcome in Oropharyngeal Squamous Cell Carcinoma: A Review.
-
Using FDG-PET activity as a surrogate for tumor cell density and its effect on equivalent uniform dose calculation.
-
Using FDG-PET to measure early treatment response in head and neck squamous cell carcinoma: quantifying intrinsic variability in order to understand treatment-induced change.
-
Utility of FDG PET/CT in inflammatory cardiovascular disease.
-
Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma.
-
Validation of consensus panel diagnosis in dementia.
-
Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
-
Value of Fluorodeoxyglucose PET/Computed Tomography Patient Management and Outcomes in Thyroid Cancer.
-
Value of Intratumoral Metabolic Heterogeneity and Quantitative 18F-FDG PET/CT Parameters in Predicting Prognosis for Patients With Cervical Cancer.
-
Value of Intratumoral Metabolic Heterogeneity and Quantitative 18F-FDG PET/CT Parameters to Predict Prognosis in Patients With HPV-Positive Primary Oropharyngeal Squamous Cell Carcinoma.
-
Value of PET/CT in the management of liver metastases, part 1.
-
Value of PET/CT in the management of primary hepatobiliary tumors, part 2.
-
Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer.
-
Ventral striatal dopamine transporter availability is associated with lower trait motor impulsivity in healthy adults.
-
Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain.
-
Yield of brain 18F-FDG PET in evaluating patients with potentially operable non-small cell lung cancer.
-
[18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy.
-
[18F]2-fluoro-2-deoxyglucose-positron emission tomography correlation of gadolinium-enhanced MR imaging of central nervous system neoplasia.
-
[18F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma.
-
[18
F]Fluoro-DCP, a first generation PET radiotracer for monitoring protein sulfenylation in vivo.
-
¹⁸F-FDG PET/CT and Colorectal Cancer: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management.
-
Keywords of People
-
Berchuck, Andrew,
James M. Ingram Distinguished Professor of Gynecologic Oncology,
Obstetrics and Gynecology, Gynecologic Oncology
-
Charles, Hal Cecil,
Adjunct Associate Professor in the Department of Radiology,
Radiology
-
McLendon, Roger Edwin,
Professor of Pathology,
Pathology
-
O'Connor, Christopher Michael,
Adjunct Professor in the Department of Medicine,
Medicine, Clinical Pharmacology
-
Patz Jr., Edward F.,
James and Alice Chen Distinguished Professor of Radiology,
Pathology
-
Sullivan, Daniel Carl,
Professor Emeritus of Radiology,
Radiology
-
Turkington, Timothy Garvey,
Associate Professor in Radiology,
Radiology